

COLLABORATING TO ACHIEVE UNIVERSAL HEALTH COVERAGE



DISCOVER HOW THE INNOVATIVE PHARMACEUTICAL INDUSTRY IS EMBRACING PARTNERSHIPS TO ACCELERATE ACTION ON SDG 3 AND OTHER GLOBAL GOALS

OUR DIVERSE PARTNERS

Either individually or by combining forces, innovative pharmaceutical companies work in collaboration with global and local stakeholders. They focus on supporting governments in the development of **whole-of-society solutions designed to strengthen health systems**, improve access to care, and close the equity gap.

To ensure these efforts stand the test of time, companies **foster local ownership** and design programs according to specific needs and existing system infrastructures.

Innovative pharmaceutical companies collaborate with...

More than
1100
PARTNERS

39

MULTI-COMPANY PROGRAMS


WE PARTNER WITH A DIVERSE RANGE OF ACTORS:



Governments



Academia and research institutes



Multilateral organizations



Global and local NGOs



Private foundations or developmental organizations



Private sector companies, such as other innovative pharmaceutical companies; generic manufacturers; biotech and diagnostic companies; data, technology, and telecom companies; services, logistics, and supply chain providers; health insurers; and more

THE MOST COMMON PARTNERS WE WORK WITH ARE:

BILL & MELINDA GATES FOUNDATION

Bill and Melinda Gates Foundation
20 programs



World Health Organization (WHO)
20 programs



US Agency for International Development (USAID)
12 programs



Medicines for Malaria Venture (MMV)
12 programs



UNICEF
10 programs

Thirty-nine collaborations are multi-company programs, where competitors put aside their differences to collectively drive progress toward shared global health goals.

We believe that, by **sharing experiences and learning from one another**, our actions will be greater than the sum of our individual efforts. These collaborative pharmaceutical industry partnerships **address systemic barriers** and lay the groundwork for long-term, **sustainable solutions**.

DISEASES AND POPULATIONS WE TARGET

Our collaborations address over 80 different diseases and are **tailored to the specific health needs** affecting the communities they serve. We support a range of **different population groups** depending on local health needs and resources.

Over
80

DIFFERENT DISEASES

OUR COLLABORATIONS ARE MAKING A DIFFERENCE ACROSS THE CONTINUUM OF CARE:



Awareness and prevention



Screening and diagnosis



Treatment



Adherence


OUR COLLABORATIONS ARE TARGETING DIFFERENT DISEASES, IN PARTICULAR:

- 1** Cancer
77 programs
- 2** Diabetes
40 programs
- 3** Tuberculosis
31 programs
- 4** Cardiovascular diseases
30 programs
- 5** HIV/AIDS
27 programs

OUR COLLABORATIONS ARE SUPPORTING DIFFERENT POPULATIONS:

- 1** People with low incomes
74 programs
- 2** Men
66 programs
- 3** Women
63 programs
- 4** Children
61 programs
- 5** Youth
40 programs
- 6** Marginalized people
36 programs

THE POPULATIONS WE SUPPORT BY DISEASE AREA:




Whether it is about R&D or complying with regulatory requirements, our industry strongly supports **evidence-based approaches**, and it strives to apply the same approach to investments in health partnerships. Measuring results helps us show what is working, what is not, and how, together with our partners, we can **adapt and scale-up our work**.

OUR GLOBAL REACH

Innovative pharmaceutical companies are working on...

250+

CROSS-SECTOR COLLABORATIONS ACROSS THE GLOBE



OUR CONTRIBUTION TO THE SDGs REACHES BEYOND HEALTH

The innovative pharmaceutical industry **discovers, develops, and delivers innovative medicines and vaccines** that enable people to live longer, healthier, and more productive lives.

In addition to our contribution to innovation, we develop **holistic programs and use a range of strategies to support better health for all** and progress toward achieving SDG 3. We equally advance SDG 17 to strengthen the means of implementation and **global partnership**, as well as other goals.

BEYOND SDG 3 AND SDG 17, OUR COLLABORATIONS ALSO SUPPORT...

3 GOOD HEALTH AND WELL-BEING



17 PARTNERSHIPS FOR THE GOALS



5 GENDER EQUALITY



25%
of our programs also support **SDG 5**

9 INDUSTRY, INNOVATION AND INFRASTRUCTURE



32%
of our programs also support **SDG 9**

10 REDUCED INEQUALITIES



30%
of our programs also support **SDG 10**

ADDRESSING ENVIRONMENT-RELATED SDGs

Innovative pharmaceutical companies are also dedicated to addressing **environment-related SDGs**, including SDG 6 on clean water and sanitation, SDG 12 on responsible production and consumption, and SDG 13 on climate action.

Companies are **working on initiatives** to reduce carbon emissions across their own operations and value chains, invest in renewable electricity and energy efficiency measures, recycle and cut water use, as well as work on bespoke projects that will positively impact the environment.¹

¹ IFPMA member companies are committed to mitigating the health challenges of climate change, however Global Health Progress hub (globalhealthprogress.org) does not track efforts toward these SDGs yet.

All data correct as of April 2023.

FIND OUT MORE:

ifpma.org



globalhealthprogress.org

